These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3137708)

  • 21. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
    Salobir B; Sabovic M; Zupan IP; Ponikvar JB
    Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis.
    Violi F; Ferro D; Basili S; Quintarelli C; Musca A; Cordova C; Balsano F
    Hepatology; 1993 Jan; 17(1):78-83. PubMed ID: 8423044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
    Bronisz A; Rosc D; Bronisz M; Szymanski W; Junik R
    Med Sci Monit; 2008 Nov; 14(11):CR574-9. PubMed ID: 18971874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of fibrinolysis in adhesion formation.
    Holmdahl L
    Eur J Surg Suppl; 1997; (577):24-31. PubMed ID: 9076449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
    Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
    Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin.
    Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
    J Biol Chem; 1987 Aug; 262(22):10819-23. PubMed ID: 3611093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
    Rość D; Drewniak W; Kotschy M; Graczykowska-Koczorowska A; Raukuć D
    Pol Merkur Lekarski; 1997 Jan; 2(7):24-5. PubMed ID: 9296893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA.
    Engesser L; Koopman J; de Munk G; Haverkate F; Nováková I; Verheijen JH; Briët E; Brommer EJ
    Thromb Haemost; 1988 Aug; 60(1):113-20. PubMed ID: 3142089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of tissue-type plasminogen activator from a culture of calf kidney cells on hemostasis and fibrinolysis in experimental nephritis].
    Andreenko GV; Podorol'skaia LV; Serebriakova TN; Liaginskiĭ AV; Egorov BB
    Biull Eksp Biol Med; 1988 Oct; 106(10):424-6. PubMed ID: 3142531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Activation of fibrynolysis in children with chronic B or C hepatitis].
    Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
    Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoradiometric quantitation of tissue plasminogen activator-related antigen in human plasma: crypticity phenomenon and relationship to plasma fibrinolysis.
    Wun TC; Capuano A
    Blood; 1987 May; 69(5):1348-53. PubMed ID: 3105618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
    Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
    J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation.
    Halvorsen S; Skjønsberg OH; Godal HC
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):133-7. PubMed ID: 8457641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of coagulation and fibrinolysis in childhood diarrhoea-associated haemolytic uraemic syndrome.
    Nevard CH; Jurd KM; Lane DA; Philippou H; Haycock GB; Hunt BJ
    Thromb Haemost; 1997 Dec; 78(6):1450-5. PubMed ID: 9423793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombolysis by a fibrin-specific antibody Fab'-urokinase conjugate.
    Bode C; Runge MS; Newell JB; Matsueda GR; Haber E
    J Mol Cell Cardiol; 1987 Apr; 19(4):335-41. PubMed ID: 3612817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-directed urokinase: a specific fibrinolytic agent.
    Bode C; Matsueda GR; Hui KY; Haber E
    Science; 1985 Aug; 229(4715):765-7. PubMed ID: 4023710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.